Q4 EPS Estimate for Option Care Health Decreased by Analyst

Option Care Health, Inc. (NASDAQ:OPCH) – William Blair cut their Q4 2024 EPS estimates for Option Care Health in a research note issued to investors on Thursday, October 31st. William Blair analyst M. Larew now forecasts that the company will post earnings per share of $0.30 for the quarter, down from their prior forecast of $0.35. The consensus estimate for Option Care Health’s current full-year earnings is $1.22 per share. William Blair also issued estimates for Option Care Health’s Q1 2025 earnings at $0.24 EPS, Q2 2025 earnings at $0.30 EPS and Q3 2025 earnings at $0.35 EPS.

A number of other research analysts have also recently weighed in on the stock. Jefferies Financial Group cut shares of Option Care Health from a “buy” rating to a “hold” rating and dropped their price objective for the company from $38.00 to $26.00 in a report on Thursday. Barrington Research decreased their price target on shares of Option Care Health from $40.00 to $32.00 and set an “outperform” rating for the company in a research note on Thursday. JMP Securities lifted their price target on shares of Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a research note on Monday, September 30th. Bank of America downgraded shares of Option Care Health from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $43.00 to $29.00 in a research report on Wednesday. Finally, Truist Financial reduced their price objective on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a research report on Friday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.60.

Option Care Health Trading Up 4.6 %

Shares of OPCH stock opened at $24.11 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.36 and a current ratio of 1.73. The stock has a market capitalization of $4.12 billion, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 1.79 and a beta of 1.29. The company has a 50 day moving average price of $30.49 and a 200 day moving average price of $29.92. Option Care Health has a fifty-two week low of $22.84 and a fifty-two week high of $34.63.

Option Care Health (NASDAQ:OPCH) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05. Option Care Health had a net margin of 4.37% and a return on equity of 15.30%. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.22 billion.

Insider Activity at Option Care Health

In related news, CFO Michael H. Shapiro sold 23,217 shares of the company’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total value of $718,566.15. Following the completion of the sale, the chief financial officer now owns 247,317 shares in the company, valued at $7,654,461.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Option Care Health news, CFO Michael H. Shapiro sold 23,217 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.95, for a total value of $718,566.15. Following the transaction, the chief financial officer now directly owns 247,317 shares of the company’s stock, valued at approximately $7,654,461.15. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Elizabeth Quadros Betten sold 47,531 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $31.09, for a total transaction of $1,477,738.79. Following the completion of the transaction, the director now directly owns 21,339 shares in the company, valued at $663,429.51. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. lifted its holdings in Option Care Health by 317.9% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 96,375 shares of the company’s stock valued at $2,670,000 after purchasing an additional 73,312 shares in the last quarter. Comerica Bank lifted its holdings in Option Care Health by 6.5% in the 1st quarter. Comerica Bank now owns 760,915 shares of the company’s stock valued at $25,521,000 after purchasing an additional 46,639 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Option Care Health by 182.9% during the 1st quarter. Janus Henderson Group PLC now owns 227,135 shares of the company’s stock worth $7,617,000 after acquiring an additional 146,837 shares during the period. Edgestream Partners L.P. lifted its holdings in shares of Option Care Health by 96.8% during the 2nd quarter. Edgestream Partners L.P. now owns 351,476 shares of the company’s stock worth $9,736,000 after acquiring an additional 172,845 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Option Care Health during the 2nd quarter worth about $973,000. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.